HER2 0, HER2 1+and HER2 2+/FISH Negative Breast Cancers Are Biologically Different

被引：0
|
作者：
Mon, Khin Su [1 ]
Zhang, Hui [1 ]
Aragao, Alessa [2 ]
Tang, Ping [1 ]
机构：
[1] Loyola Univ Med Ctr, Maywood, IL 60153 USA
[2] Mayo Clin, Rochester, MN USA
来源：
LABORATORY INVESTIGATION | 2023年 / 103卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
193
引用
收藏
页码：S182 / S183
页数：2
相关论文
共 50 条
  • [21] Breast cancer with HER2 FISH test result in group 2: Should HER2 test be repeated?
    Chen, Hui
    Wang, Minhua
    Sun, Hongxia
    Gu, Jun
    Tang, Zhenya
    Tang, Guilin
    Sfamenos, Steven
    Robinson, Melissa
    Sahin, Aysegul
    CANCER RESEARCH, 2020, 80 (04)
  • [22] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Sasagu Kurozumi
    Mary Padilla
    Masafumi Kurosumi
    Hiroshi Matsumoto
    Kenichi Inoue
    Jun Horiguchi
    Izumi Takeyoshi
    Tetsunari Oyama
    Jim Ranger-Moore
    D. Craig Allred
    Eslie Dennis
    Hiroaki Nitta
    Breast Cancer Research and Treatment, 2016, 158 : 99 - 111
  • [23] HER2 Gene Protein Assay Is Useful to Determine HER2 Status of Breast Carcinoma with HER2 IHC and FISH Double Equivocal Results
    Li, Zaibo
    Hou, Yanjun
    Nitta, Hiroaki
    LABORATORY INVESTIGATION, 2016, 96 : 54A - 54A
  • [24] The Bioinformatics Analysis of miRNAs Signatures Differentially Expressed in HER2(+) Versus HER2(-) Breast Cancers
    Nie, Weiwei
    Jin, Lei
    Wang, Yanru
    Wang, Zexing
    Guan, Xiaoxiang
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2013, 28 (01) : 71 - 76
  • [25] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Kurozumi, Sasagu
    Padilla, Mary
    Kurosumi, Masafumi
    Matsumoto, Hiroshi
    Inoue, Kenichi
    Horiguchi, Jun
    Takeyoshi, Izumi
    Oyama, Tetsunari
    Ranger-Moore, Jim
    Allred, D. Craig
    Dennis, Eslie
    Nitta, Hiroaki
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 99 - 111
  • [26] Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer
    Lauterlein, Jens-Jacob L.
    Petersen, Eva R. B.
    Olsen, Dorte Aa
    Ostergaard, Birthe
    Brandslund, Ivan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (05) : 877 - 883
  • [27] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Chen, Zhaoxu
    Jia, Huiqing
    Zhang, Huina
    Chen, Lifang
    Zhao, Peng
    Zhao, Jing
    Fu, Guangming
    Xing, Xiaoming
    Li, Yujun
    Wang, Chengqin
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
  • [28] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Zhaoxu Chen
    Huiqing Jia
    Huina Zhang
    Lifang Chen
    Peng Zhao
    Jing Zhao
    Guangming Fu
    Xiaoming Xing
    Yujun Li
    Chengqin Wang
    Breast Cancer Research and Treatment, 2023, 202 : 313 - 323
  • [29] HER2 Positive Breast Cancers with Progression
    Solanki, Malvika
    Chitambar, Christopher
    Jorns, Julie
    LABORATORY INVESTIGATION, 2019, 99
  • [30] Impact of HER2 Copy Number in IHC HER2 2+/FISH Positive Breast Cancer on Outcome of Adjuvant Trastuzumab Treatment
    Borley, A.
    Mercer, T.
    Morgan, M.
    Barrett-Lee, P.
    Jasani, B.
    JOURNAL OF PATHOLOGY, 2013, 231 : 19 - 19
12345